Search Results - "Davis Jr, John C."

A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 by Baruch, Amos, Luca, Diana, Kahn, Robert S., Cowan, Kyra J., Leabman, Maya, Budha, Nageshwar R., Chiu, Cecilia P.C., Wu, Yan, Kirchhofer, Daniel, Peterson, Andrew, Davis Jr, John C., Tingley, Whittemore G.

“…Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates low‐density lipoprotein (LDL) receptors, thereby leading to a rise in…”
Get full text

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis by Suppiah, Ravi, Judge, Andrew, Batra, Rajbir, Flossmann, Oliver, Harper, Lorraine, Höglund, Peter, Javaid, M. Kassim, Jayne, David, Mukhtyar, Chetan, Westman, Kerstin, Davis, John C., Hoffman, Gary S., McCune, W. Joseph, Merkel, Peter A., St.Clair, E. William, Seo, Philip, Spiera, Robert, Stone, John H., Luqmani, Raashid

“…Objective To create a prognostic tool to quantify the 5‐year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and…”
Get full text

Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis by Wang, Yehong, Zhu, Rui, Xiao, Jim, Davis Jr, John C., Mandema, Jaap W., Jin, Jin Y., Tang, Meina T.

“…The objective of this study was to assess the relationship between short‐term and long‐term treatment effects measured by the American College of Rheumatology…”
Get full text

IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis by Kelley, James M., Monach, Paul A., Ji, Chuanyi, Zhou, Yebin, Wu, Jianming, Tanaka, Sumiaki, Mahr, Alfred D., Johnson, Sharleen, McAlear, Carol, Cuthbertson, David, Carette, Simon, Davis, John C., Dellaripa, Paul F., Hoffman, Gary S., Khalidi, Nader, Langford, Carol A., Seo, Phillip, St. Clair, E. William, Specks, Ulrich, Stone, John H., Spiera, Robert F., Ytterberg, Steven R., Merkel, Peter A., Edberg, Jeffrey C., Kimberly, Robert P.

“…Granulomatosis with polyangiitis (Wegener's) is a rare autoimmune neutrophil-mediated vasculitis that can cause renal disease and mucosal manifestations…”
Get full text

Adalimumab Reduces Pain, Fatigue, and Stiffness in Patients with Ankylosing Spondylitis: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS) by REVICKI, Dennis A, LUO, Michelle P, WORDSWORTH, Paul, WONG, Robert L, CHEN, Naijun, DAVIS, John C

“…Objective To evaluate the effect of adalimumab on pain, fatigue, and stiffness in patients with active ankylosing spondylitis (AS). Methods The Adalimumab…”
Get full text

Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis by Brionez, Tamar F, Assassi, Shervin, Reveille, John D, Learch, Thomas J, Diekman, Laura, Ward, Michael M, Davis, Jr, John C, Weisman, Michael H, Nicassio, Perry

“…Functional status is an integral component of health-related quality of life in patients with ankylosing spondylitis (AS). The purpose of this study was to…”
Get full text

Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis by Ward, Michael M., Hendrey, Matthew R., Malley, James D., Learch, Thomas J., Davis, John C., Reveille, John D., Weisman, Michael H.

“…Objective To improve prognostic ability in ankylosing spondylitis (AS), we sought to identify demographic, clinical, and immunogenetic characteristics…”
Get full text

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments by Scheerens, Heleen, Su, Zheng, Irving, Bryan, Townsend, Michael J, Zheng, Yanan, Stefanich, Eric, Chindalore, Vishala, Bingham, 3rd, Clifton O, Davis, Jr, John C

“…The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of the humanized anti-CD4 monoclonal…”
Get full text

Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis by Walter P Maksymowych, A Robin Poole, Lori Hiebert, Alison Webb, Mirela Ionescu, Tatiana Lobanok, Lindsay King, John C Davis, Jr

“…OBJECTIVE: Anti-tumor necrosis factor-alpha (TNF-alpha) therapies are not only beneficial for reducing symptoms in rheumatoid arthritis (RA) but also for…”
Get full text

The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event by Jodi K Sebastian, Barbara Voetsch, John H Stone, Zurina Romay-Penabad, Grace H Lo, Nancy B Allen, John C Davis, Jr, Gary S Hoffman, W Joseph McCune, E William St Clair, Ulrich Specks, Robert Spiera, Joseph Loscalzo, Silvia Pierangeli, Peter A Merkel, Wegener's Granulomatosis Etanercept Trial Research Group

“…OBJECTIVE: Venous thrombotic events (VTE), including both deep venous thrombosis and pulmonary emboli, are now recognized as an important complication of…”
Get full text

Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept by John C Davis, Jr, Désirée M F M Van der Heijde, Maxime Dougados, Jurgen Braun, John J Cush, Daniel O Clegg, Robert D Inman, Todd de Vries, Wayne H Tsuji

“…OBJECTIVE: To examine the baseline demographic and disease characteristics that might influence improvement as measured by the Assessment in Ankylosing…”
Get full text

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) by Kalunian, Kenneth C, Merrill, Joan T, Maciuca, Romeo, McBride, Jacqueline M, Townsend, Michael J, Wei, Xiaohui, Davis, Jr, John C, Kennedy, William P

“…To examine the safety and efficacy of rontalizumab, a humanised IgG1 anti-interferon α (anti-IFN-α) monoclonal antibody, in patients with moderate-to-severe…”
Get more information

Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study) by Baruch, Amos, PhD, Mosesova, Sofia, PhD, Davis, John D., PhD, Budha, Nageshwar, PhD, Vilimovskij, Alexandr, MD, Kahn, Robert, MD, Peng, Kun, PhD, Cowan, Kyra J., PhD, Harris, Laura Pascasio, MPH, Gelzleichter, Thomas, PhD, Lehrer, Josh, MD, Davis, John C., MD, Tingley, Whittemore G., MD

“…RG7652 (MPSK3169A), a fully human immunoglobulin G1 (IgG1) monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), blocks…”
Get full text

Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort by Lee, Wonuk, Reveille, John D, Davis, John C, Learch, Thomas J, Ward, Michael M, Weisman, Michael H

“…Objective: To examine the clinical and radiographic features in men and women in the Prospective Study of Outcomes in Ankylosing Spondylitis cohort, a large…”
Get full text

Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α by Gorman, Jennifer D, Sack, Kenneth E, Davis, John C

“…Ankylosing spondylitis is difficult to treat — those affected often have acute inflammation and discomfort even decades after the onset of the disease. Since…”
Get full text

Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in wegener granulomatosis by FINKIELMAN, Javier D, MERKEL, Peter A, HUMMEL, Amber M, VISS, Margaret A, PEIKERT, Tobias, STONE, John H, SPECKS, Ulrich, SCHROEDER, Darrell, HOFFMAN, Gary S, SPIERA, Robert, CLAIR, E. William St, DAVIS, John C, MCCUNE, W. Joseph, LEARS, Andrea K, YTTERBERG, Steven R

“…The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management of patients with Wegener granulomatosis remains controversial. To…”
Get full text

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE by Kennedy, William P, Maciuca, Romeo, Wolslegel, Kristen, Tew, Wei, Abbas, Alexander R, Chaivorapol, Christina, Morimoto, Alyssa, McBride, Jacqueline M, Brunetta, Paul, Richardson, Bruce C, Davis, John C, Behrens, Timothy W, Townsend, Michael J

“…Objectives The interferon (IFN) signature (IS) in patients with systemic lupus erythematosus (SLE) includes over 100 genes induced by type I IFN pathway…”
Get full text

Ankylosing Spondylitis: Patterns of Radiographic Involvement-A Re-examination of Accepted Principles in a Cohort of 769 Patients by JANG, Jennifer H, WARD, Michael M, RUCKER, Adam N, REVEILLE, John D, DAVIS, John C, WEISMAN, Michael H, LEARCH, Thomas J

“…To re-examine the patterns of radiographic involvement in ankylosing spondylitis (AS). This prospective study had institutional review board approval, and 769…”
Get full text

Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study by Merkel, Peter A, Lo, Grace H, Holbrook, Janet T, Tibbs, Andrea K, Allen, Nancy B, Davis, Jr, John C, Hoffman, Gary S, McCune, W Joseph, St Clair, E William, Specks, Ulrich, Spiera, Robert, Petri, Michelle, Stone, John H

“…Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known. To measure the incidence of VTEs in patients…”
Get full text

ANCA Are Detectable in Nearly All Patients with Active Severe Wegener’s Granulomatosis by Finkielman, Javier D., MD, Lee, Augustine S., MD, Hummel, Amber M., BS, Viss, Margaret A., BS, Jacob, Gregory L., BS, Homburger, Henry A., MD, Peikert, Tobias, MD, Hoffman, Gary S., MD, Merkel, Peter A., MD, MPH, Spiera, Robert, MD, St. Clair, E. William, MD, Davis, John C., MD, MPH, McCune, W. Joseph, MD, Tibbs, Andrea K., BS, Ytterberg, Steven R., MD, Stone, John H., MD, MPH, Specks, Ulrich, MD

“…Abstract Background The pathogenic significance of antineutrophilic cytoplasmic antibodies (ANCA) in Wegener’s granulomatosis is controversial. Their presence…”
Get full text